Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Risuteganib is an anti-integrin peptide and a derivative of RGD peptide (Item No. 14501).1 Risuteganib (400 µM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells.2 It decreases the expression of BAX, VEGFA, and ITB1 in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.3 Risuteganib arrests aberrant blood vessel growth mediated by αVβ3, αVβ5, and α5β1 integrins in vivo.1
WARNING This product is not for human or veterinary use.
1. Integrin peptide therapy: The first wet AMD experience. Invest. Opth. Vis. Sci. 54(15), 2177 (2013).
2. Risuteganib protects against hydroquinone-
3. Differential effects of risuteganib and bevacizumab on AMD cybrid cells. Exp. Eye Res. 203, 108287 (2021).